<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633317</url>
  </required_header>
  <id_info>
    <org_study_id>NMRPD1K0861</org_study_id>
    <nct_id>NCT04633317</nct_id>
  </id_info>
  <brief_title>Aerosolized Colistin to Mechanical Ventilated Patients With Pneumonia</brief_title>
  <acronym>CRGNB</acronym>
  <official_title>Aerosolized Colistin to Mechanical Ventilated Patients With CRGNB Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the effect of aerosolized colistin on to&#xD;
      ventilated patients with carbapenem-resistant gram negative bacteria pneumonia. We&#xD;
      hypothesize that adjunct aerosolized colistin, which achieve high drug concentrations in the&#xD;
      airway, would more effectively treat the penumbra.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To treat respiratory infection of patients with mechanical ventilation, greater systemic&#xD;
      antibiotic dose is required through the patient's venous injection. In this trial, patients&#xD;
      with arbapenem-resistant gram negative bacteria pneumonia (CRGNB)were assigned to adjunct&#xD;
      aerosolized colistin delivered by a jet nebulizer or a vibrating mesh nebulizer comparing to&#xD;
      or standard intravenous injection by a randomizing protocol.&#xD;
&#xD;
      Need for a systemic antibiotic was determined by the clinical physician. Comparisons were&#xD;
      made between standard care and study drug for their effects on bacteria eradiation, incidence&#xD;
      of nephrotoxicity, and oxygenation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pulmonary infection score</measure>
    <time_frame>7-10 days</time_frame>
    <description>The clinical pulmonary infection score calculated on the basis of points assigned for various signs and symptoms of pneumonia (eg, fever and extent of oxygenation impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator pressure control level</measure>
    <time_frame>7-10 days</time_frame>
    <description>Ventilator pressure control level setting indirectly indicate lung compliance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>Group A Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Regimen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A pneumatic nebulizer</intervention_name>
    <description>Inhaled colistimethate sodium generated by a pneumatic nebulizer</description>
    <arm_group_label>Group A Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A vibrating mesh nebulizer</intervention_name>
    <description>Inhaled colistimethate sodium generated by a vibrating mesh nebulizer</description>
    <arm_group_label>Group A Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients received invasive mechanical ventilation &gt;48 hours&#xD;
&#xD;
          -  Diagnosed with pneumonia caused by carbapenem resistance gram negative bacteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  receiving colistin &gt; 3 days&#xD;
&#xD;
          -  recurrent pneumonia caused by carbapenem resistance gram negative bacteria&#xD;
&#xD;
          -  allergy to colistin or polymyxin B drugs&#xD;
&#xD;
          -  immunocompromised, defined as neutropenia ANC&lt;500 cells/ul&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  received chemotherapy with 3 months&#xD;
&#xD;
          -  renal function deficiency (creatinine clearance &lt; 30 ml/min)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Ling Lin, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Ling Lin, MS</last_name>
    <phone>+886-32118800</phone>
    <phone_ext>5228</phone_ext>
    <email>huiling@mail.cgu.eud.tw</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung University</investigator_affiliation>
    <investigator_full_name>Hui-Ling Lin</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

